Para adaptarse a todas sus necesidades de expresión, Invitrogen ofrece vectores de destino Gateway™ de vanguardia de destino para laMás información
Have Questions?
Número de catálogo
Cantidad
11812013
también denominado 11812-013
6 μg
Número de catálogo 11812013
también denominado 11812-013
Precio (MXN)
-
Cantidad:
6 μg
Para adaptarse a todas sus necesidades de expresión, Invitrogen ofrece vectores de destino Gateway™ de vanguardia de destino para la expresión en célula de E. coli, insecto, levadura o mamífero, así como para la producción de proteína nativa o proteínas de fusión N o C-terminal. Los vectores de destino Gateway™ tienen sitios attR para la recombinación con cualquier fragmento flanqueado por attL, independientemente de si se trata de un clon de entrada o de un clon Ultimate™ RF. La siguiente tabla enumera la amplia gama de vectores de destino disponibles.
Materiales adicionales necesarios, disponibles por separado: Clon de entrada Gateway™, mezcla de enzimas Gateway™ LR Clonase™ y tampón de reacción.
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Sistema constitutivo o inducibleConstitutivo
Tipo de entregaTransfección
Para utilizar con (aplicación)Expresión constitutiva
Tipo de productoVector de expresión de destino del sistema Gateway
Cantidad6 μg
Agente de selección (eucariótico)Geneticin™ (G-418)
VectorpDEST
Método de clonaciónGateway
Línea de productosGateway
PromotorCMV
Etiqueta de proteínaEtiqueta GST
Unit SizeEach
Contenido y almacenamiento
Todos los vectores de destino se suministran liofilizados y superenrollados.
Preguntas frecuentes
Can I perform the single-step protocol for the BP/LR Clonase reaction using BP Clonase enzyme and LR Clonase enzyme instead of BP Clonase II enzyme and LR Clonase II enzyme?
In the single-step protocol for the BP/LR Clonase reaction, we would not recommend substituting the BP Clonase II/LR Clonase II enzymes with BP Clonase /LR Clonase enzymes as this would result in very low recombination efficiency.
Do you have a recommended single-step protocol for BP/LR recombination?
Yes, we have come up with a single-step protocol for BP/LR Clonase reaction (http://www.thermofisher.com/us/en/home/life-science/cloning/gateway-cloning.html#1), where DNA fragments can be cloned into Destination vectors in a single step reaction, allowing you to save time and money.
How can I move my gene of interest from a Gateway-adapted expression clone to a new Destination vector as I have lost the entry clone?
We would recommend performing a BP reaction with a Donor vector in order to obtain an entry clone. This entry clone can then be used in an LR reaction with the Destination vector to obtain the new expression clone.
Can I purchase the 5X LR Clonase buffer or 5X BP Clonase buffer separately?
We do not offer the 5X LR Clonase buffer and 5X BP Clonase buffer as standalone products. They are available as part of the enzyme kits.
Do you offer Gateway vectors for expression in plants?
We do not offer any Gateway vectors for expression in plants.
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.
Authors: Gomes M D; Lecker S H; Jagoe R T; Navon A; Goldberg A L;
Journal:Proc Natl Acad Sci U S A
PubMed ID:11717410
'Muscle wasting is a debilitating consequence of fasting, inactivity, cancer, and other systemic diseases that results primarily from accelerated protein degradation by the ubiquitin-proteasome pathway. To identify key factors in this process, we have used cDNA microarrays to compare normal and atrophying muscles and found a unique gene fragment that ... More
Mediation of the DCC apoptotic signal by DIP13 alpha.
Authors: Liu Jiayou; Yao Fayi; Wu Ruping; Morgan Michael; Thorburn Andrew; Finley Russell L Jr; Chen Yong Q;
Journal:J Biol Chem
PubMed ID:12011067
DCC (deleted in colorectal cancer) is a candidate tumor suppressor gene. However the function of DCC remains elusive. Previously, we demonstrated that forced expression of DCC induces apoptosis or cell cycle arrest (Chen, Y. Q., Hsieh, J. T., Yao, F., Fang, B., Pong, R. C., Cipriano, S. C. & Krepulat, ... More